Remdesivir clinical trials
Also written Veklury and GS-5734.
How each study uses remdesivir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the remdesivir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 22 Oct 2020 · VEKLURY · NDA 214787 (FDA, Drugs@FDA)
- European Union
- 3 Jul 2020 · Veklury · EMEA/H/C/005622 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
48 studies that test it; most in 2020 (28)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 1 |
| 2020 | 28 |
| 2021 | 8 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 39
Gilead Sciences (6) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Capital Medical University (2) · QuantumLeap Healthcare Collaborative (1) · University of Melbourne (1) · Lisa Barrett (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · University of Derby (1)
Often tested with
Tested in the same studies.
Hydroxychloroquine (8) · Lopinavir-ritonavir drug combination (5) · Tocilizumab (4) · Interferon beta-1a (4) · Nirmatrelvir (3) · Ritonavir (3) · Ivermectin (3) · Nirmatrelvir and ritonavir drug combination (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test remdesivir, phase 3 first.
- Sep 2027A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedPhase 3 · Pfizer
- Dec 2026Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant PatientsPhase 2 · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Dec 2026OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy TrialPhase 2 · ANRS, Emerging Infectious Diseases
- Jan 2027Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Phase 2 · University of Oxford
- Nov 2027Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised IndividualsPhase 2 · Fred Hutchinson Cancer Center
Studies
Open first, then newest update. How each study uses remdesivir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 48
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Remdesivir
- OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy TrialRecruitingPhase 2ANRS, Emerging Infectious DiseasesNCT05587894Written as Veklury
- A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely ImmunocompromisedRecruitingPhase 3PfizerNCT07013474Written as remdesivir
- Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised IndividualsRecruitingPhase 2Fred Hutchinson Cancer CenterNCT06817889Written as Remdesivir
- Adaptive Dengue Antiviral Platform TrialRecruitingPhase 2Oxford University Clinical Research Unit, VietnamNCT06551844Written as Remdesivir 100mg
- Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)RecruitingPhase 2University of OxfordNCT05041907Written as Remdesivir
- Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant PatientsRecruitingPhase 2Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaNCT07197164Written as Remdesivir (RDV)
- Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSVRecruitingPhase 2PENTA FoundationNCT06873633Written as Remdesivir
- Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical TrialRecruitingPhase 4Mount Sinai Hospital, CanadaNCT06792214Written as Remdesivir
- LUSZ Treatment Efficacy in Hospitalized COVID-19 PatientsRecruitingPhase 1Lebanese UniversityNCT05925140Written as Remdesivir (RDV)
- Trial of Treatments for COVID-19 in Hospitalized AdultsCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT04315948Written as Remdesivir
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsActive, not recruitingPhase 2QuantumLeap Healthcare CollaborativeNCT04488081Written as Remdesivir
- An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.CompletedPhase 4University of DerbyNCT05911906Written as Remdesivir
- ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04843761Written as Remdesivir
- Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT06729593Written as Remdesivir
- An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANYWithdrawnPhase 2/3Professor Dr. Bernd MühlbauerNCT04575064Written as Remdesivir
- Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingPhase 3University of MelbourneNCT04483960Written as Remdesivir
- Study of Remdesivir in Participants Below 18 Years Old With COVID-19CompletedPhase 2/3Gilead SciencesNCT04431453Written as Remdesivir
- Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized PatientsActive, not recruitingPhase 2Lisa BarrettNCT04321993Written as Remdesivir (antiviral)
- Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 PatientsCompletedPhase 4Mansoura University HospitalNCT05502081Written as Remdesivir
See all 48 studies that test remdesivir →
Given beside what is tested · 25 — remdesivir is usual care or a partner of the new treatment
- AGILE (Early Phase Platform Trial for COVID-19)RecruitingPhase 1/2University of LiverpoolNCT04746183Written as ALG-097558 and Remdesivir
- SARS-CoV-2 Human Challenge Characterisation StudyCompletedNot applicableImperial College LondonNCT04865237Written as Remdesivir
- AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780437Written as Remdesivir
- Baricitinib in Hospitalized Covid-19 Patients With Diabetes MellitusWithdrawnPhase 3Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersNCT04970719Written as Remdesivir
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)TerminatedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780541Written as Remdesivir
- BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780424Written as Remdesivir
- MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780463Written as Remdesivir
- LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780268Written as Remdesivir
- VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT05780281Written as Remdesivir
- Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 PatientsTerminatedPhase 3Daewoong Pharmaceutical Co. LTD.NCT04713176Written as DWJ1248 with Remdesivir
- Immune Modulators for Treating COVID-19CompletedPhase 3Daniel BenjaminNCT04593940Written as Remdesivir
- ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04501978Written as Remdesivir
- COVID-19 and Anti-CD14 Treatment TrialTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04391309Written as remdesivir
- ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04988035Written as Remdesivir
- ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04583969Written as Remdesivir
- ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19CompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT04583956Written as Remdesivir
- Adaptive COVID-19 Treatment Trial 4 (ACTT-4)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04640168Written as Remdesivir
- Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)CompletedPhase 3University of MinnesotaNCT04546581Written as Remdesivir
- Adaptive COVID-19 Treatment Trial 3 (ACTT-3)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04492475Written as Remdesivir
- Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04401579Written as Remdesivir
Showing 20 of 25.
As the comparator · 3 — what is tested is compared with remdesivir
- A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult SubjectsCompletedPhase 1Heronova PharmaceuticalsNCT06860282Written as Remdesivir
- Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 InfectionTerminatedPhase 3PharmaMarNCT04784559Written as Remdesivir
- IFN-beta 1b and Remdesivir for COVID19Status unknownPhase 2The University of Hong KongNCT04647695Written as Remdesivir
Codes
What other systems call remdesivir · ClinicalTrials.gg INT000432
- MeSH (NLM) C000606551remdesivirConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3QKI37EEHEREMDESIVIRConfirmed FDA, NLM, Wikidata
- RxNorm 2284718Confirmed FDA, Wikidata
- Wikidata Q28209496remdesivirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152185RemdesivirOne source FDA
- DrugBank DB14761One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000606551 | remdesivir | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3QKI37EEHE | REMDESIVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2284718 | — | Confirmed FDA, Wikidata |
| Wikidata | Q28209496 | remdesivir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152185 | Remdesivir | One source FDA |
| DrugBank | DB14761 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.